MANY SAY THE SHORTAGE IS ABOUT
THE SAME OR WORSE THAN IT WAS
BACK IN MAY.
THE U.S. CONTINUES TO TEST
AND POSSIBLY RELEASE A
CORONAVIRUS VACCINE, BUT AS DR.
MARIA SIMBRA REPORTS, RELEASING
A VACCINE BEFORE IT IS FULLY
TESTED AND READY COULD HAVE
NEGATIVE CONSEQUENCES.
Reporter: IN A RUSH TO BEAT
COVID-19 A VACCINE COULD BE
MADE AVAILABLE THROUGH THE FOOD
AND DRUG ADMINISTRATION'S
EMERGENCY USE AUTHORIZATION.
EMERGENCY USE AUTHORIZATION
IS WHEN THE FDA IN A CRISES
WILL REVIEW THE DATA THAT HAS
BEEN PROVIDED TO THEM.
Reporter: THIS AUTHORIZATION
SPEEDS UP GETTING TESTS AND
DROPPINGS TO MARKETED FOR
SPECIFIC USE FOR A LIMITED
TIME.
TYPICALLY A SERIES OF BIGGER
AND BIGGER STUDIES HAVE SAFETY
AND EFFECTIVENESS LEAD TO FDA
APPROVAL.
IT CAN TAKE MANY YEARS FOR
ALL OF THAT TO HAPPEN.
WE HAVE SOMEWHAT ACCELERATED
THAT TASK.
Reporter: THE U.S.
GOVERNMENT HAS INVESTED $10
BILLION IN EIGHT DIFFERENT
VACCINES UNDER DEVELOPMENT BY
MILLIONS OF DOSES READY TO GOIVE
IF THE FDA GIVES THE GREEN
LIGHT.
I WONDER IF WE CAN GET THE
DATA TO REALLY EVALUATE IT.
Reporter: MOVING TOO QUICKLY
COULD LEAD TO DRAWBACKS.
MANY COULD BE APPREHENSIVE.
IF YOU RUN THE RISK OF A
POPULATION NOT TRUSTING THAT A
VACCINE IS SAFE OR EFFECTIVE.
AND WE REALLY NEED PEOPLE TO
STEP UP AND WANT TO RECEIVE A
VACCINE TO STOP SPREADING THIS.
Reporter: THERE COULD BE
UNFORESEEN SIDE EFFECTLESS.
WE DO REPORT THOSE BACK TO
THE FDA AND THEN THEY TAKE THAT
INTO CONSIDERATION ON WHETHER
THAT VACCINE OR TREATMENT
SHOULD REMAIN IN THE MARKET.
Reporter: A VACCINE WITH
ONLY WEAK EFFECTIVENESS COULD
BE A PROBLEM TOO.
THEY MAY HAVE A FALSE SENSE
OF I HAVE BEEN VACCINATED, I
CAN'T GET COVID, THEREFORE, I
CAN DO WHAT I WANT.
Reporter: TRANSPARENCY WILL
BE IMPORTANT TO SHOW THE PUBLIC
WHY A VACCINE IS BEING PUT
FORTH.
THE END OF THE YEAR MAY BE TOO
SOON TO GET THERE.
IS 2021 A REASONABLE TIME?
SURE, IF WE HAVE THE RESOURCES
AND WE DEDICATE OUR TIME.
I THINK ALL OF US ARE EXCITED
FOR A VACCINE, BUT WE DON'T
WANT TO RUSH IT.
Reporter: A CONCERN, SHE
